| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal HST32: Olipudase alfa for treating acid sphingomyelinase deficiency (Niemann–Pick disease) type AB and type B |
|
Medicine details |
|
| Medicine name | olipudase alfa (Xenpozyme®) |
| Formulation | intravenous infusion |
| Reference number | 3247 |
| Indication | Enzyme replacement therapy for the treatment of non-Central Nervous System (CNS) manifestations of Acid Sphingomyelinase Deficiency (ASMD) in paediatric and adult patients with type A/B or type B |
| Company | Sanofi |
| BNF chapter | Nutrition & blood |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 26/07/2022 |
| NICE guidance | |